全部照片(1)
About This Item
經驗公式（希爾表示法）:
C7H2N2Br4
CAS號碼:
分子量：:
433.72
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推薦產品
化驗
≥98% (HPLC)
形狀
powder
溶解度
DMSO: >10 mg/mL at 60 °C, clear
儲存溫度
2-8°C
SMILES 字串
Brc1c(Br)c(Br)c2[nH]cnc2c1Br
InChI
1S/C7H2Br4N2/c8-2-3(9)5(11)7-6(4(2)10)12-1-13-7/h1H,(H,12,13)
InChI 密鑰
LOEIRDBRYBHAJB-UHFFFAOYSA-N
應用
TBBz has been used as a CK2 inhibitor in HeLa cells and rat septal neurons.
生化／生理作用
Cell-permeable CK2 inhibitor.
TBBz is a cell-permeable Casein Kinase-2 (CK2) inhibitor. CK2 inhibitors, 4,5,6,7-tetrabromobenzotriazole (TBBt, Sigma Cat. # T0826) and rabromobenzimidazole (TBBz), the latter of which was shown to discriminate between different molecular forms of CK2 in yeast. TBBt, with a pK(a) ~5, exists in solution at physiological pH almost exclusively (>99%) as the monoanion; whereas TBBz, with a pKa ~9, is predominantly (>95%) in the neutral form, both of obvious relevance to their modes of binding. In vitro, TBBt inhibits different forms of CK2 with Ki values ranging from 80 to 210 nM. TBBz discriminates better between CK2 forms, with Ki values ranging from 70-510 nM. TBBz is more effective than TBBt in inducing apoptosis and to a lesser degree, necrosis in transformed human cell lines. Dvelopment of shRNA strategies for the selective knockdown of the CK2α and CK2α′ isoforms reinforces the foregoing results, indicating that inhibition of CK2 leads to attenuation of proliferation.
準備報告
TBBz is soluble in DMSO (60 deg C) at a concentration that is greater than 10 mg/ml.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Florence Chaverneff et al.
Journal of neurochemistry, 109(3), 733-743 (2009-02-19)
The combination of bone morphogenetic protein 7 (BMP7) and neurotrophins (e.g. brain-derived neurotrophic factor, BDNF) protects septal neurons during hypoglycemic stress. We investigated the signaling mechanisms underlying this synergistic protection. BMP7 (5 nM) increased phosphorylation and nuclear translocation of BMP-responsive
Jacob P Turowec et al.
Oncotarget, 4(4), 560-571 (2013-04-20)
Protein kinase CK2 has emerged as a promising candidate for the treatment of a number of cancers. This enzyme is comprised of two catalytic subunits (CK2 and/or CK2α') that form complexes with homodimers of regulatory CK2β subunits. While catalytic and
Maria Russo et al.
Oncotarget, 8(26), 42571-42587 (2017-05-11)
Despite the encouraging results of the innovative therapeutic treatments, complete remission is uncommon in patients affected by chronic lymphocytic leukaemia, which remains an essentially incurable disease. Recently, clinical trials based on BH3-mimetic drugs showed positive outcomes in subjects with poor
Laszlo Gyenis et al.
Journal of proteome research, 10(11), 4887-4901 (2011-09-23)
Protein kinases have emerged as attractive targets for treatment of several diseases prompting large-scale phosphoproteomics studies to elucidate their cellular actions and the design of novel inhibitory compounds. Current limitations include extensive reliance on consensus predictions to derive kinase-substrate relationships
James S Duncan et al.
Molecular & cellular proteomics : MCP, 7(6), 1077-1088 (2008-02-09)
Recently protein kinases have emerged as some of the most promising drug targets; and therefore, pharmaceutical strategies have been developed to inhibit kinases in the treatment of a variety of diseases. CK2 is a serine/threonine-protein kinase that has been implicated
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務